People · Operator
Named in public records as an officer, director or promoter · active 2016–2016 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| PellePharm, Inc. | — | Biotechnology | Series A | $19.6M | $271.1M | 2016 |
Mark De Souza, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark De Souza, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark De Souza | 1 | 10 |
| Frank McCormick | 1 | 7 |
| Neil Kumar | 1 | 3 |
| Neil Kumar, PH.D. | 1 | 1 |
| Frank McCormick, Ph.D. | 1 | 1 |
| Ervin Epstein, M.D. | 1 | 1 |
| Jean Tang, M.D., Ph.D. | 1 | 1 |
| Sanuj Ravinddran, M.D. | 1 | 1 |
| Ervin Epstein | 1 | 1 |
| Jean Y. Tang, M.D., Ph.D. | 1 | 1 |
| Jean Tang | 1 | 1 |
| Katrin Andreasson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.